Life Science Company News
Back to overview

Biopharmaceuticals Market, 2025 - Market is Projected to grow by 8.7% Through to 2025 and Reach $446 Billion

DUBLIN, July 19, 2019 /PRNewswire/ -- The "Biopharmaceuticals - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.

Global demand for Biopharmaceuticals by product is led by Monoclonal Antibodies (moAb), estimated at US$82.3 billion (33.2% share) in 2018, and is also projected to witness the fastest CAGR of 10.8% between 2018 and 2025. The global market for biopharmaceuticals in 2019 is expected to reach US$269.3 billion.

The biopharmaceuticals market is driven by various factors, such as increase in elderly population, surge in prevalence of chronic diseases like cancer, HIV/AIDS and diabetes, and increase in adoption of biopharmaceuticals globally. Biopharmaceuticals offer several benefits including highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.

The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.

Research Findings & Coverage

  • The Biopharmaceuticals global market explored in this study with respect to product types and application areas
  • The study extensively analyzes above mentioned product types and applications of Biopharmaceuticals in each major region/country globally for the analysis period
  • Lanadelumab Effective in Reducing Swelling Attacks in Patients with Hereditary Angioedema
  • Emerging Innovations and their Impact on Biopharma Manufacturing in the Coming Years
  • Monoclonal Antibodies Show High Potential Against Zika Virus Infection
  • Portable Bioreactor Produces Biopharmaceutical Drugs on Demand at a Point of Care
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled - 58
  • The industry guide includes the contact details for 843 companies

Key Topics Covered:

Part A: Global Market Perspective

1. Introduction
1.1 Product Outline
1.1.1 Biopharmaceuticals
1.1.2 Evolution of the Biopharmaceuticals
1.1.3 Biosimilars
1.1.4 Commercialization of Biopharmaceuticals
1.1.5 Biopharmaceuticals Regulations
1.1.6 Production of Biopharmaceuticals
1.1.6.1 Microbial Cells
1.1.6.2 Mammalian Cells
1.1.6.3 Plant Cells
1.1.6.4 Transgenics
1.1.7 Disposable Manufacturing with Single-Use Systems
1.1.8 Characterization of Biopharmaceuticals
1.1.9 Delivery Systems for Biopharmaceuticals
1.1.10 Categorization of Biopharmaceuticals
1.1.10.1 Monoclonal Antibodies
1.1.10.2 Erythropoietin (EPO)
1.1.10.3 Biotech Vaccines
1.1.10.4 Recombinant Human (RH) Insulin
1.1.10.5 Granulocyte Colony-Stimulating Factor (G-CSF)
1.1.10.6 Interferons (IFNs)
1.1.10.7 Human Growth Hormones
1.1.10.8 Other Biopharmaceuticals
1.1.10.8.1 Blood Factors (Factor VIII and Factor IX)
1.1.10.8.1.1 Factor VIII
1.1.10.8.1.2 Factor IX
1.1.10.8.2 Thrombolytic Agents (Tissue Plasminogen Activator)
1.1.10.8.2.1 Function of tPA
1.1.10.8.2.2 Clinical Uses of tPA
1.1.10.8.2.3 Recombinant Tissue Plasminogen Activators (rtPA)
1.1.10.8.3 Interleukin-Based Products
1.1.10.8.3.1 Human Interleukins
1.1.10.8.4 Tumor Necrosis Factor
1.1.10.8.5 Therapeutic Enzymes
1.1.10.8.5.1 A Few Important Therapeutic Enzymes

2. Key Market Trends
2.1 Pembrolizumab Prolongs Overall Survival in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
2.2 Lanadelumab Effective in Reducing Swelling Attacks in Patients with Hereditary Angioedema
2.3 FDA and Other Federal Health Agencies to Address the Challenges in Developing New Antimicrobials
2.4 Isolated Human Monoclonal Antibodies that Neutralize Norovirus
2.5 Emerging Innovations and their Impact on Biopharma Manufacturing in the Coming Years
2.6 Monoclonal Antibodies Show High Potential Against Zika Virus Infection
2.7 Rapid Technological Advancements are Changing the Biopharmaceuticals Industry
2.8 Portable Bioreactor Produces Biopharmaceutical Drugs on Demand at a Point of Care

3. Key Global Players

  • Abbott Laboratories, Inc. (United States)
  • AbbVie Inc. (United States)
  • Amgen, Inc. (United States)
  • Astrazeneca Plc (United Kingdom)
  • Bayer AG (Germany)
  • Biocon Ltd. (India)
  • Biogen Inc (United States)
  • Boehringer Ingelheim GmbH (Germany)
  • Bristol-Myers Squibb Company (United States)
  • Eli Lilly and Company (United States)
  • Glaxosmithkline, Plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Janssen Pharmaceuticals, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Novo Nordisk, Inc. (United States)
  • Pfizer Inc (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Genentech, Inc. (United States)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UCB S.A. (Belgium)

4. Key Business and Product Trends

  • Eli Lilly Acquires Loxo Oncology to expand its Oncology Portfolio
  • FDA Expands ALIMTA (Pemetrexed) Label with Combination of KEYTRUDA (Pembrolizumab) and Platinum Chemotherapy for the First-Line NSCLC Treatment
  • GlaxoSmithKline (GSK) Acquires TESARO, a Biopharmaceutical Company for $5.1 Billion
  • FDA Approves Adacel (Tdap) Vaccine for Repeat Vaccinations
  • Sanofi to Enter into License Agreement with Biomunex to Develop Antibody Therapeutics
  • AbSci and Sanofi to Enter into Manufacturing Partnership
  • Takeda Completes Acquisition of Shire Plc
  • 19 December 2018Biogen Collaborates With C4 Therapeutics to Develop Treatments for Neurological Conditions
  • Abbvie to Collaborate With Tizona to Develop Antibody Immunotherapy
  • Bristol-Myers Squibb to Acquire Celgene for $74-Billion
  • FDA Approved Sprycel (Dasatinib) Tablets in Combination with Chemotherapy in Certain Pediatric Patients
  • Novartis to Acquires Endocyte, a US-based biopharmaceutical company for $2.1 Billion
  • Abbvie Submits NDA to FDA and MAA to EMA for Upadacitinib
  • GSK and Pfizer to Merge Consumer Healthcare Businesses to Form a Joint Venture
  • Lilly Signs Research Collaboration and License Agreement with Aduro Biotech
  • Lilly to Acquire Hydra's Pre-Clinical Pain Program TRPA1
  • Roche Subsidiary Genentech to Acquire NASH-Focused Jecure Therapeutics
  • Pfizer Gains Global Patent License for AbbVie's HUMIRA (Adalimumab)
  • Amgen and Provention Bio Enters Into Co-Development Agreement
  • Astrazeneca to Sell Synagis US Rights to Sobi for $1.5 Billion
  • Lilly Partners with NextCure to Develop Immuno-Oncology Medicines
  • AstraZeneca's MedImmune Expands Innate Pharma Oncology Collaboration
  • Abbvie Teams Up With Morphic Therapeutic For Fibrotic Disease Treatments
  • Roche to Acquire Immuno-Oncology Company Tusk Therapeutics
  • Janssen Partners With Arrowhead to Treat Hepatitis B
  • Merck to collaborate with Dragonfly Therapeutics on Solid-Tumor Immunotherapies
  • Sanofi to Enter Research Collaboration with Dyadic
  • Pfizer Teams Up With BioNTech to Develop mRNA -Based Flu Vaccines for Prevention of Influenza
  • Amgen to Build Next-Generation Biomanufacturing Plant Rhode Island
  • Takeda Pharmaceutical to Acquire TiGenix, a Biopharmaceutical Company
  • GSK Signs R&D Partnership with 23andme
  • Novartis Inks $1.1 Billion Monoclonal Antibody Deal With MorphoSys and Galapagos
  • Novartis Partners With CELLforCURE to Manufacture CAR-T Therapies
  • Abbvie and Calico Collaborated to Develop T-Cell Therapies for Cancer
  • Sanofi to Partner with Translate Bio $850 Million mRNA Vaccine Development Deal
  • Sanofi to Acquire Ablynx in $4.8 Billion Deal
  • Alexion Teams Up With Complement to Treat Neurodegenerative Disorders
  • WuXi Biologics to Invest $60 Million in US Plant
  • FDA Approval for Samsung BioLogics's mab Drug Substance Manufacturing Plant
  • Novartis to Acquire AveXis, Gene-Therapy Biotech Company for $8.7 Billion
  • Lilly to Buy ARMO Biosciences
  • Janssen Biotech to Acquire BeneVir Biopharm
  • Merck to Expand mRNA Cancer Vaccines Collaboration with Moderna
  • Janssen to Collaborate With Bristol-Myers Squibb to Develop Factor XIa (FXIa) Inhibitors
  • Alexion to Buy Sweden-Based Wilson Therapeutics
  • Lilly to Partner with Sigilon to Develop Encapsulated Cell Therapies
  • Boehringer Ingelheim Inks $1.7 Billion Immuno-Oncology Deal With OSE Immunotherapeutics
  • Pfizer to Enter Asset Contribution Agreement with Allogene Therapeutics
  • Sanofi to Acquire Biogen's Bioverativ, a Hemophilia-focused company
  • AstraZeneca's MedImmune to Spins off Biotech Company Focused on Autoimmune Diseases
  • Abbvie to Sign Strategic Collaboration with Alector Partner on Alzheimer's Disease Immunotherapies
  • Lilly and CureVac Inks $1.8 Billion Deal to Develop mRNA Cancer Vaccines
  • J&J Terminates Two Drugs Sirukumab and Talacotuzumab from Pipeline
  • J&J's Stelara Received FDA Approval for Expanded Indication
  • AbbVie and BMS Partners on clinical research collaboration
  • J&J to Enter R&D Partnership with Health and Human Services (HHS)

5. Recent Biopharmaceuticals Approvals

6. Global Market Overview
6.1 Global Biopharmaceuticals Market Overview by Product Type
6.1.1 Global Biopharmaceuticals Product Market Overview by Geographic Region
6.1.1.1 Monoclonal Antibodies (moAb)
6.1.1.2 Biotech Vaccines
6.1.1.3 Recombinant Human (RH) Insulin
6.1.1.4 Erythropoietin
6.1.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
6.1.1.6 Interferons
6.1.1.7 Human Growth Hormones (HGH)
6.1.1.8 Other Biopharmaceuticals
6.2 Global Biopharmaceuticals Market Overview by Application
6.2.1 Global Biopharmaceuticals Application Market Overview by Geographic Region
6.2.1.1 Oncology
6.2.1.2 Autoimmune Disorders
6.2.1.3 Diabetes
6.2.1.4 Inflammatory and Infectious Diseases
6.2.1.5 Neurological Diseases
6.2.1.6 Cardiovascular Diseases
6.2.1.7 Other Applications

Part B: Regional Market Perspective

Regional Market Overview

7. North America

Major Market Players

  • Abbott Laboratories, Inc. (United States)
  • AbbVie Inc. (United States)
  • Alder Biopharmaceuticals Inc. (United States)
  • Alexion Pharmaceuticals, Inc (United States)
  • Amgen, Inc. (United States)
  • Analytical Biological Services Inc (United States)
  • Array Biopharma Inc. (United States)
  • Atlanta Biologicals, Inc (United States)
  • Biogen Inc (United States)
  • Bristol-Myers Squibb Company (United States)
  • Charles River Laboratories International, Inc. (United States)
  • Eli Lilly and Company (United States)
  • Fujifilm Diosynth Biotechnologies USA Inc (United States)
  • Genentech, Inc. (United States)
  • Johnson & Johnson (United States)
  • Janssen Pharmaceuticals, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Millennium Pharmaceuticals, Inc. (United States)
  • Novo Nordisk, Inc. (United States)
  • Pfizer Inc (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • Sanofi-Aventis U.S. LLC (United States)
  • Seattle Genetics, Inc (United States)
  • Soligenix, Inc. (United States)
  • Sunovion Pharmaceuticals Inc. (United States)

8. Europe

Major Market Players

  • 3P Biopharmaceuticals S.L. (Spain)
  • Applikon Biotechnology B.V. (The Netherlands)
  • Albumedix Ltd. (United Kingdom)
  • Astrazeneca Plc (United Kingdom)
  • Bayer AG (Germany)
  • Boehringer Ingelheim GmbH (Germany)
  • Cellgenix GmbH (Germany)
  • Evotec AG (Germany)
  • Glaxosmithkline, Plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Roche Holding AG (Switzerland)
  • Sanofi (France)
  • UCB S.A. (Belgium)

9. Asia-Pacific

Major Market Players

  • Beijing SL Pharmaceutical Co Ltd (China)
  • Beijing Tiantan Biological Products Co Ltd (China)
  • Biocon Ltd. (India)
  • Biological E Limited (India)
  • Cadila Healthcare Limited (Zydus Cadila) (India)
  • Celltrion, Inc. (South Korea)
  • Glenmark Pharmaceuticals Limited (India)
  • GVK Biosciences Pvt Ltd (India)
  • Hualan Biological Engineering Inc (China)
  • Reliance Life Sciences Pvt Ltd (India)
  • RPG Life Sciences Limited (India)
  • Samsung Biologics Co Ltd (South Korea)
  • Shanghai Institute of Biological Products (China)
  • Shantha Biotechnics Ltd (India)
  • Sun Pharmaceutical Industries Ltd (India)
  • Suven Life Sciences Ltd (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Torrent Pharmaceuticals Limited (India)

10. South America

11. Rest of World

Major Market Players

  • Teva Pharmaceutical Industries Ltd. (Israel)
  • UNV Medicine Ltd. (Israel)

For more information about this report visit https://www.researchandmarkets.com/r/bfcung

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/biopharmaceuticals-market-2025---market-is-projected-to-grow-by-8-7-through-to-2025-and-reach-446-billion-300887971.html

SOURCE Research and Markets

- 19 Jul 2019
Back to overview

Enhance your business development with Biotechgate
Try for free »